
Kim Popovits, Chairman, CEO & President, Genomic Health

Kim Popovits, Chairman, CEO & President, Genomic Health
Kim Popovits, the Chairman, CEO & President of Genomic Health, will be honored at PMWC 2013 Israel* for her pioneering efforts in successfully advancing personalized medicine into the clinical adoption phase, both in the US and globally. After working on Herceptin at Genentech, Kim oversaw commercialization efforts at Genomic Health starting in 2002, eventually bringing one of the first personalized medicine diagnostic test, OncoType DX, into clinics around the world in 2006. Israel’s Clalit was the first ex-US HMO to reimburse the assay.
Kim Popovits has served as president and CEO of Genomic Health since 2009 and as president and chief operating officer since 2002. Prior to joining Genomic Health, Popovits served in various roles, most recently as senior vice president of marketing and sales, at Genentech, Inc. During her 15 years at Genentech, she led the successful commercialization of 14 new therapies, including Herceptin. Before joining Genentech, Popovits served as division manager for American Critical Care. In 2008, Popovits was named Woman of the Year by the Women Health Care Executives, and she has been named one of the Most Influential Women in the Bay Area by The San Francisco Business Times from 2006 to 2011. She holds a bachelor of arts in business from Michigan State University.